JP2023524430A5 - - Google Patents

Info

Publication number
JP2023524430A5
JP2023524430A5 JP2022565760A JP2022565760A JP2023524430A5 JP 2023524430 A5 JP2023524430 A5 JP 2023524430A5 JP 2022565760 A JP2022565760 A JP 2022565760A JP 2022565760 A JP2022565760 A JP 2022565760A JP 2023524430 A5 JP2023524430 A5 JP 2023524430A5
Authority
JP
Japan
Prior art keywords
days
administration
immunomodulatory compound
cells
cell therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022565760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524430A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/029503 external-priority patent/WO2021222330A2/en
Publication of JP2023524430A publication Critical patent/JP2023524430A/ja
Publication of JP2023524430A5 publication Critical patent/JP2023524430A5/ja
Pending legal-status Critical Current

Links

JP2022565760A 2020-04-28 2021-04-27 Bcma指向性t細胞療法と免疫調節化合物との併用 Pending JP2023524430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063016983P 2020-04-28 2020-04-28
US63/016,983 2020-04-28
PCT/US2021/029503 WO2021222330A2 (en) 2020-04-28 2021-04-27 Combination of bcma-directed t cell therapy and an immunomodulatory compound

Publications (2)

Publication Number Publication Date
JP2023524430A JP2023524430A (ja) 2023-06-12
JP2023524430A5 true JP2023524430A5 (cg-RX-API-DMAC10.html) 2024-05-09

Family

ID=76502791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022565760A Pending JP2023524430A (ja) 2020-04-28 2021-04-27 Bcma指向性t細胞療法と免疫調節化合物との併用

Country Status (11)

Country Link
US (1) US20230165872A1 (cg-RX-API-DMAC10.html)
EP (1) EP4142723A2 (cg-RX-API-DMAC10.html)
JP (1) JP2023524430A (cg-RX-API-DMAC10.html)
KR (1) KR20230015921A (cg-RX-API-DMAC10.html)
CN (1) CN116157125A (cg-RX-API-DMAC10.html)
AU (1) AU2021263765A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022021788A2 (cg-RX-API-DMAC10.html)
CA (1) CA3181399A1 (cg-RX-API-DMAC10.html)
IL (1) IL297688A (cg-RX-API-DMAC10.html)
MX (1) MX2022013530A (cg-RX-API-DMAC10.html)
WO (1) WO2021222330A2 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113573719A (zh) 2018-11-08 2021-10-29 朱诺治疗学股份有限公司 治疗和t细胞调节的方法和组合
CN118201618A (zh) * 2021-04-16 2024-06-14 细胞基因公司 与bcma定向t细胞疗法的组合疗法
EP4412713A1 (en) * 2021-10-05 2024-08-14 GlaxoSmithKline Intellectual Property Development Ltd Combination therapies for treating cancer
CA3205511A1 (en) * 2023-04-19 2025-03-17 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2025137751A1 (pt) * 2023-12-26 2025-07-03 Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein Polinucleotídeo, receptor de antígeno quimérico, vetor, composição, método para produção de célula imune efetora modificada e uso do polinucleotídeo

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7204296B2 (en) 2004-07-26 2007-04-17 Metal Casting Technology, Incorporated Method of removing a fugitive pattern from a mold
EP2520643B8 (en) 2007-12-07 2019-11-27 Miltenyi Biotec B.V. & Co. KG Sample processing systems and methods
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープCity of Hope 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3172231B1 (en) 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
BR112017005766B1 (pt) 2014-09-22 2022-10-25 Sacmi Cooperativa Meccanici Imola Societa' Cooperativa Linha de produção para a fabricação de produtos, de forma sucessiva e método para a produção de produtos individuais, de forma sucessiva, em ciclo contínuo, em uma linha de produção
HRP20210582T1 (hr) 2014-12-05 2021-09-03 Memorial Sloan Kettering Cancer Center Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe
CN113698497A (zh) 2014-12-05 2021-11-26 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
KR102427334B1 (ko) 2016-04-01 2022-08-03 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
MX2019005277A (es) * 2016-11-04 2019-09-27 Bluebird Bio Inc Composiciones de celulas t con car anti-bcma.
PL3618842T3 (pl) * 2017-05-01 2024-02-19 Juno Therapeutics, Inc. Kombinacja terapii komórkowej i związku immunomodulującego
JP7258009B2 (ja) * 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
EP4549554A3 (en) 2017-07-29 2025-08-06 Juno Therapeutics, Inc. Reagents for expanding cells expressing recombinant receptors
US11066475B2 (en) * 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
PL3796912T3 (pl) * 2018-05-23 2023-09-11 Celgene Corporation Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
US12473345B2 (en) * 2018-11-01 2025-11-18 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
CN113573719A (zh) * 2018-11-08 2021-10-29 朱诺治疗学股份有限公司 治疗和t细胞调节的方法和组合
CN113747896A (zh) * 2019-04-22 2021-12-03 斯塔顿治疗公司 来那度胺和其他免疫调节剂的连续递送
EP4054623A1 (en) * 2019-11-07 2022-09-14 Juno Therapeutics, Inc. Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4 ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]- piperidine-2,6-dione

Similar Documents

Publication Publication Date Title
US20250262318A1 (en) Methods and pharmaceutical composition for the treatment of cancer
AU2017302668B9 (en) Combination therapies of chimeric antigen receptors and PD-1 inhibitors
KR102717188B1 (ko) 암의 치료를 위한 키메라 항원 수용체
TWI750110B (zh) 使用人類化抗-bcma嵌合抗原受體治療癌症
US20200055948A1 (en) Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP4461308B1 (en) Toxicity management for anti-tumor activity of cars
JP2022512971A5 (cg-RX-API-DMAC10.html)
RU2744841C2 (ru) Комбинация
US20220175725A1 (en) Combination of immunotherapies with mdm2 inhibitors
JP2021512107A5 (cg-RX-API-DMAC10.html)
JP2024540275A5 (cg-RX-API-DMAC10.html)
JP2024513054A5 (cg-RX-API-DMAC10.html)
TW202208419A (zh) 靶向愛潑斯坦巴爾病毒的tcr-t細胞療法
JP2022554353A5 (cg-RX-API-DMAC10.html)
EP4142722A1 (en) Methods of treating cytokine-related adverse events
JP2024514163A5 (cg-RX-API-DMAC10.html)
JP2024540320A5 (cg-RX-API-DMAC10.html)
RU2809160C2 (ru) Виды комбинированной терапии с использованием химерных антигенных рецепторов и ингибиторов pd-1
HK40116181B (en) Toxicity management for anti-tumor activity of cars
HK40116181A (en) Toxicity management for anti-tumor activity of cars
HK40039113A (en) Toxicity management for anti-tumor activity of cars
EA048837B1 (ru) Ступенчатая анти-cd19 терапия
RU2021118587A (ru) Антитела, специфичные в отношении нектина-2 человека
RU2019138707A (ru) Сочетание клеточной терапии и иммуномодуляторного соединения